ACS

Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress

Retrieved on: 
Monday, October 30, 2023

CHATHAM, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced data from two oral presentations which were delivered recently at the American College of Surgeons (ACS) Clinical Congress 2023, and The International Pancreas and Islet Transplant Association (IPITA), the International Xenotransplantation Association (IXA), and the Cell Transplant and Regenerative Medicine Society (CTRMS) Joint Congress by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in October 2023. The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection. Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com.

Key Points: 
  • The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection.
  • Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com .
  • include data demonstrating the use of TNX-1500 as maintenance therapy after xeno heart transplant in non-human primates.
  • In both studies, genetically engineered (GE) pigs in baboon transplants were treated with cold-perfused ischemia minimization and a novel costimulation-based immunosuppressive regimen including TNX-1500.

Integration of Multiple Biomarkers Fuels Robust 12.14% CAGR in Global Cardiac Biomarkers Market Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 6, 2023

The global cardiac biomarkers market is projected to experience robust growth, reaching $26.43 billion by 2028, with a compound annual growth rate (CAGR) of 12.14% from 2022 to 2028.

Key Points: 
  • The global cardiac biomarkers market is projected to experience robust growth, reaching $26.43 billion by 2028, with a compound annual growth rate (CAGR) of 12.14% from 2022 to 2028.
  • Key Market Trends & Drivers:
    Integration of Multiple Cardiac Biomarkers: Healthcare professionals are increasingly combining information from various cardiac biomarkers to gain a comprehensive understanding of a patient's cardiac health.
  • Increasing R&D Activities: The market is witnessing a surge in research and development (R&D) activities focused on novel cardiac biomarkers.
  • The global cardiac biomarkers market is highly competitive, with players ranging from pharmaceutical companies and diagnostic manufacturers to biotechnology firms and research institutions.

LivaNova Reports Third-Quarter 2023 Results

Retrieved on: 
Wednesday, November 1, 2023

Adjusted operating income for the third quarter of 2023 was $45.0 million, as compared to adjusted operating income of $36.6 million for the third quarter of 2022.

Key Points: 
  • Adjusted operating income for the third quarter of 2023 was $45.0 million, as compared to adjusted operating income of $36.6 million for the third quarter of 2022.
  • Third-quarter 2023 adjusted diluted earnings per share was $0.73, as compared to adjusted diluted earnings per share of $0.58 in the third quarter of 2022.
  • LivaNova now expects revenue for full-year 2023 to grow between 9% and 11% on a constant-currency basis.
  • Adjusted diluted earnings per share for 2023 is now expected to be in the range of $2.60 to $2.80, assuming a fully diluted share count of 54 million for full-year 2023.

Air Conditioning Market size to grow by USD 19.65 billion from 2022 to 2027, Rise in residential construction activity to drive market growth - Technavio

Retrieved on: 
Thursday, November 2, 2023

Hence, the increasing demand for inverter air conditioners to save energy will drive the growth of the global air conditioning (AC) market during the forecast period.

Key Points: 
  • Hence, the increasing demand for inverter air conditioners to save energy will drive the growth of the global air conditioning (AC) market during the forecast period.
  • Some of the key Air Conditioning Market Players:
    The air conditioning market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
  • The market share growth by the splits segment will be significant for overall market growth during the forecast period.
  • The global railway AC units market size is estimated to grow by USD 3,116.8 million between 2022 and 2027 at a CAGR of 5.93%.

Toray ACS launched the fashion CAD software package "CREACOMPO® GLOBAL" in the US market

Retrieved on: 
Wednesday, November 1, 2023

TOKYO, Nov. 1, 2023 /PRNewswire/ -- Toray Advanced Computer Solution, Inc. (hereinafter "Toray ACS") introduced a fashion CAD software package with 2D (pattern making) and 3D (virtual muslin making and 3D fitting simulation) capabilities into the US market on October 23, 2023.

Key Points: 
  • TOKYO, Nov. 1, 2023 /PRNewswire/ -- Toray Advanced Computer Solution, Inc. (hereinafter "Toray ACS") introduced a fashion CAD software package with 2D (pattern making) and 3D (virtual muslin making and 3D fitting simulation) capabilities into the US market on October 23, 2023.
  • Toray ACS, a CAD software developer for the fashion industry, has launched a new package of fashion CAD software called "CREACOMPO®GLOBAL" in the US market.
  • "CREACOMPO" is a well-known fashion CAD brand in the Japanese market and is used by most Japanese apparel companies.
  • Since its debut in 1998, Toray ACS has been developing software with a relentless attention to detail.

TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights

Retrieved on: 
Wednesday, October 25, 2023

MOUNTAIN VIEW, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive integrated artificial intelligence (AI) heart care solutions, today announced results from three clinical studies supporting the use of advanced coronary computed tomography angiography (CCTA)-based technologies in the assessment of patients with suspected coronary artery disease (CAD). Results from the ADVANCE-DK Plaque, EMERALD II, and FASTTRACK-CABG studies were presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

Key Points: 
  • Results from the ADVANCE-DK Plaque, EMERALD II, and FASTTRACK-CABG studies were presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
  • The data build on HeartFlow’s extensive body of clinical evidence supporting AI-powered non-invasive diagnostic testing for patients with CAD.
  • Together, this comprehensive solution offers valuable data not currently available with traditional non-invasive diagnostics tools.
  • FASTTRACK-CABG is an investigator-driven study sponsored by the University of Galway, Ireland and co-funded by HeartFlow and GE HealthCare.

Avertix Data Presented at TCT 2023 Shows 150% Increase in Medication Adjustments of Antiarrhythmics for High-Risk Heart Attack Survivors

Retrieved on: 
Tuesday, October 24, 2023

EATONTOWN, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), creator of the world’s first and only real-time heart attack detection and patient alerting system designed to improve long-term management and outcomes of recurrent events in high-risk patients who have survived one or more heart attacks, announced The Guardian System™ data was presented today at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. The study found an increase of more than 150% in new administration or titration of medications related to rate and rhythm abnormalities in patients whose Guardian™ alarms were activated compared to patients whose alarms were off.

Key Points: 
  • The Guardian System, the first and only FDA-approved implantable heart attack detection and warning system, also alerts patients in real-time of abnormal heart rates and rhythms and provides a recent history of intracardiac recordings.
  • “This data has provided us with valuable insights into addressing the care needs of high-risk Acute Coronary Syndrome (ACS) patients,” said Dr. Kaplan.
  • “With a career-long commitment to improving patient wellbeing and advancing cardiovascular research, The Guardian System is changing the paradigm for heart attack survivors,” said Dr. Gibson.
  • In addition to endpoints assessing ACS events, the trial collected data on medication usage and adjustments.

Valvoline Instant Oil Change Locations Raise Funds for the Fight Against Cancer

Retrieved on: 
Thursday, October 19, 2023

ORANGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Throughout the month of October, select Valvoline Instant Oil Change℠ (VIOC) locations are offering customers an opportunity to donate at the time of their oil change to support American Cancer Society (ACS) and its Road To Recovery program.

Key Points: 
  • ORANGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Throughout the month of October, select Valvoline Instant Oil Change℠ (VIOC) locations are offering customers an opportunity to donate at the time of their oil change to support American Cancer Society (ACS) and its Road To Recovery program.
  • Transportation barriers are the #1 reason for missed cancer appointments and the Road To Recovery program provides free rides to treatment for cancer patients.
  • “Thanks to VIOC’s continued partnership and steadfast commitment to the fight against cancer, more patients will get access to life-saving treatment.”
    To help raise additional funds for the American Cancer Society, download a coupon and find participating Valvoline Instant Oil Change locations at ValvolineFightsCancer.com .
  • For every coupon redeemed, Valvoline Instant Oil Change will donate $5.

Sparrow Pharmaceuticals Doses First Patient in Phase 2 ACSpire Study of SPI-62 for Autonomous Cortisol Secretion

Retrieved on: 
Tuesday, October 24, 2023

This trial will complement the ongoing Phase 2 RESCUE study (NCT number: NCT05307328 ) for the treatment of ACTH-dependent Cushing’s syndrome.

Key Points: 
  • This trial will complement the ongoing Phase 2 RESCUE study (NCT number: NCT05307328 ) for the treatment of ACTH-dependent Cushing’s syndrome.
  • The study will examine SPI-62's effect on morbidities of hypercortisolism including diabetes or impaired glucose tolerance, hyperlipidemia, hypertension, and osteopenia.
  • Sparrow is actively enrolling up to 30 participants in ACSpire at sites in the United States, soon to be joined by sites in Romania, France, and the United Kingdom.
  • To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .

Pharmatech Associates Showcases Strategic Program Development for Drug Sponsors and Innovators at CPHI Barcelona 2023

Retrieved on: 
Tuesday, October 24, 2023

Pharmatech Associates experts will be on hand at CPHI Barcelona 2023, October 24-26, 2023, at the U.S. Pharmacopeia (USP) booth, Stand 4H17, zone Excipients.

Key Points: 
  • Pharmatech Associates experts will be on hand at CPHI Barcelona 2023, October 24-26, 2023, at the U.S. Pharmacopeia (USP) booth, Stand 4H17, zone Excipients.
  • View the full release here: https://www.businesswire.com/news/home/20231023128034/en/
    Pharmatech Associates' Lawrence De Belder (continuous manufacturing lead) and Sireesha Yadlapalli (CEO) will present four expert live sessions on stage at CPHI Barcelona, Oct 24 & 25, 2023.
  • Continuous Improvement Through Continuous Manufacturing, Lawrence De Belder, Continuous Manufacturing Practice Lead, Pharmatech Associates, Oct 25, 2023, 15:05 – 15:25 (CET) Room: 4.4, Conference Centre 4.
  • For more about Pharmatech Associates sessions and USP’s activities at CPHI Barcelona, please visit here .